Treatment of cognitive impairment in HIV-infected patients receiving tuberculosis therapy: results of an observational program
Bibliographic record
Abstract
Objective. To obtain data on the efficacy and safety of Prospekta in the therapy of cognitive impairment (CI) in HIV-infected patients with chemotherapy for tuberculosis. Patients and methods. A total of 120 patients older than 18 years (mean age 43.9 years) who met the inclusion criteria were included in the observational program. All participants were assessed initially, after 4, 8, 12, 24 weeks using the Montreal Cognitive Assessment Scale (MoCA), and quality of life using the European Quality of Life Questionnaire. Patients were randomized into two groups: the group of starting administration of Prospekta (n = 60) – patients received Prospect for 12 weeks against the background of tuberculosis chemotherapy, the group of delayed administration of Prospekta (n = 60) – patients received tuberculosis chemotherapy for 12 weeks without Prospekta. After 12 weeks, the therapy was changed: patients in the initial prescription group continued TB chemotherapy for another 12 weeks without Prospecta. Patients in the delayed prescription group were treated with Prospecta for 12 weeks against the background of chemotherapy. Patients were ranked into three subgroups depending on the severity of CI: subjective CI (SubCI; n = 8), moderate CI (MCI; n = 59), severe CI (SCI; n = 53). Patients' demographic characteristics were comparable across groups/subgroups. Results. Patients with SubCI in the Prospekta starter group showed an increase in mean MoCA score from 27.1 ± 1.3 to 29.1 ± 0.9 by 12 weeks of therapy (vs. 26.0 to 27.0 in the delayed group, p = 1.0000); after changing therapy with Prospekta exclusion at visit 4, there was a change in mean MoCA score of -0.1 by 24 weeks of therapy (vs. 2.0 on Prospekta addition, p = 1.0000). Patients with MCI in the Prospekta starter group showed an increase in mean MoCA score by 12 weeks of therapy from 22.2 ± 2.0 to 25.7 ± 2.3 (vs. 20.0 ± 1.2 to 20.9 ± 2.6 points in the delayed prescription group, p ≤ 0.0001), after changing the therapy with Prospekta exclusion at visit 4, there was a 0.1 change in the mean MoCA score by 24 weeks of treatment (vs. 3.4 points on Prospekta addition, p ≤ 0.0001). Patients with SCI in the Prospekta starter group showed an increase in mean MoCA score by 12 weeks of therapy from 15.8 ± 2.5 to 22.3 ± 3.8 (vs. 16.3 ± 1.7 to 18.7 ± 2.5 points in the delayed prescription group, p = 0.0063), after the change of therapy with Prospekta exclusion at visit 4, there was a 0.8 change in the mean MoCA score by 24 weeks of treatment (vs. 4.0 points on Prospekta addition, p ≤ 0.0001). Patients in the Prospekta starter group showed a 10-fold advantage in quality of life after 4 weeks compared to respondents in the delayed prescription group. A total of 9 AEs were recorded in 4 patients, among which 8 AEs were mild and 1 AE was severe. All of them were unrelated to the drug. Conclusion. The efficacy and safety of Prospekta in the treatment of SubCI, MCI and SCI in HIV-associated patients receiving tuberculosis chemotherapy have been demonstrated. Key words: cognitive disorders of varying severity, pulmonary tuberculosis, HIV infection, Prospekta, chemotherapy
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.005 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".